Canaccord Genuity Maintains Hold and Raises Price Target on ISIS Pharmaceuticals (ISIS)

August 7, 2012 9:52 AM EDT Send to a Friend
Get Alerts ISIS Hot Sheet
Price: $38.83 -3.36%

Rating Summary:
    6 Buy, 7 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 25 | Down: 20 | New: 23
Trade ISIS Now!
Join SI Premium – FREE
Today analysts at Canaccord Genuity maintained a Hold rating on ISIS Pharmaceuticals (NASDAQ: ISIS) and raised their price target to $11.00 (from $9.00). The increased PT ascribes greater value to the company's pipeline.

"We continue to view ISIS's pipeline as progressing nicely, with the next lead product, TTR (TTR amyloidosis, partnered with GSK) to enter P3 for familial polyneuropathy in H2," said analyst Salveen Richter.

For an analyst ratings summary and ratings history on ISIS Pharmaceuticals click here. For more ratings news on ISIS Pharmaceuticals click here.

Shares of ISIS Pharmaceuticals closed at $13.19 yesterday.




You May Also Be Interested In


Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Canaccord Genuity

Add Your Comment